{"id":75325,"date":"2026-08-19T12:38:40","date_gmt":"2026-08-19T04:38:40","guid":{"rendered":"https:\/\/flcube.com\/?p=75325"},"modified":"2026-08-19T12:38:41","modified_gmt":"2026-08-19T04:38:41","slug":"shanghai-yizhong-pharmaceuticals-yxc-002-wins-ind-approval-fourth-generation-brain-penetrant-egfr-tki-for-non-small-cell-lung-cancer-overcomes-c797s","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=75325","title":{"rendered":"Shanghai Yizhong Pharmaceutical&#8217;s YXC\u2011002 Wins IND Approval \u2013 Fourth\u2011Generation Brain\u2011Penetrant EGFR\u2011TKI for Non\u2011Small Cell Lung Cancer Overcomes C797S Resistance"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Shanghai Yizhong Pharmaceutical Co., Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/688091:SHA\">SHA: 688091<\/a>) announced that the <strong>Investigational New Drug (IND)<\/strong> application for its <strong>self\u2011developed innovative drug YXC\u2011002<\/strong>, targeting <strong>non\u2011small cell lung cancer (NSCLC)<\/strong>, has been officially approved, clearing the way for clinical trials of a next\u2011generation therapy designed to address key resistance and brain\u2011metastasis challenges in EGFR\u2011driven disease.<\/p>\n\n\n\n<h2 id=\"h-ind-approval-summary\" class=\"wp-block-heading\">IND Approval Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Shanghai Yizhong Pharmaceutical Co., Ltd (SHA: 688091)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>YXC\u2011002 (self\u2011developed innovative drug)<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Fourth\u2011generation, highly brain\u2011penetrant <strong>EGFR\u2011TKI<\/strong><\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Non\u2011small cell lung cancer (NSCLC)<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>IND officially approved<\/td><\/tr><tr><td><strong>Intellectual Property<\/strong><\/td><td>Proprietary IP, independently developed<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>19 Aug 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-yxc-002\" class=\"wp-block-heading\">Drug Profile \u2013 YXC\u2011002<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Class:<\/strong> Novel small\u2011molecule candidate, a <strong>fourth\u2011generation EGFR\u2011TKI<\/strong> with a unique and innovative molecular design and clear pharmacological mechanisms<\/li>\n\n\n\n<li><strong>Target Spectrum:<\/strong> A range of <strong>classic and non\u2011classic EGFR driver mutations and resistance mutations<\/strong> in NSCLC<\/li>\n\n\n\n<li><strong>CNS Coverage:<\/strong> Effectively addresses treatment of patients with <strong>central nervous system (CNS) metastases<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-differentiation-three-key-advantages\" class=\"wp-block-heading\">Differentiation \u2013 Three Key Advantages<\/h2>\n\n\n\n<h3 id=\"h-overcomes-resistance\" class=\"wp-block-heading\">Overcomes Resistance<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Overcomes treatment failure caused by the <strong>C797S resistance point mutation<\/strong> seen in earlier\u2011generation EGFR inhibitors<\/li>\n\n\n\n<li>Maintains <strong>high selectivity for wild\u2011type EGFR<\/strong>, resulting in lower wild\u2011type EGFR\u2011related toxicity<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-superior-anti-tumor-efficacy\" class=\"wp-block-heading\">Superior Anti\u2011Tumor Efficacy<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Compared to <strong>BDTX\u20111535<\/strong>, a novel fourth\u2011generation EGFR inhibitor currently in Phase II clinical trials, YXC\u2011002 demonstrates <strong>superior anti\u2011tumor efficacy<\/strong><\/li>\n\n\n\n<li>Particularly pronounced against <strong>sensitizing mutations (19del)<\/strong> and <strong>triple mutations (L858R\u2011T790M\u2011C797S)<\/strong><\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-enhanced-cns-penetration\" class=\"wp-block-heading\">Enhanced CNS Penetration<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Its <strong>unique chemical structure<\/strong> enables enhanced penetration across the <strong>blood\u2011brain barrier<\/strong>, a critical advantage given the high incidence of CNS metastases in EGFR\u2011mutant NSCLC<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Crowded but High\u2011Stakes Market:<\/strong> EGFR\u2011mutant NSCLC is one of the largest targeted\u2011therapy segments in China, with resistance to third\u2011generation TKIs (e.g., after C797S emergence) creating a clear opening for fourth\u2011generation agents.<\/li>\n\n\n\n<li><strong>CNS Metastasis Unmet Need:<\/strong> Brain metastases are a leading cause of treatment failure in EGFR\u2011mutant NSCLC; YXC\u2011002&#8217;s brain\u2011penetrant design positions it where many competitors struggle.<\/li>\n\n\n\n<li><strong>Competitive Benchmarking:<\/strong> The direct preclinical comparison to <strong>BDTX\u20111535<\/strong>, the most advanced fourth\u2011generation EGFR inhibitor, signals YXC\u2011002&#8217;s ambition to compete head\u2011to\u2011head in this emerging drug class \u2014 pending clinical confirmation.<\/li>\n\n\n\n<li><strong>Watch Items:<\/strong> First\u2011in\u2011human trial design and enrollment, early safety and efficacy readouts (particularly in C797S\u2011mutant and CNS\u2011metastatic cohorts), and potential partnering interest from larger oncology players.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development, regulatory outcomes, and commercial expectations for YXC\u2011002. Actual results may differ due to risks including early\u2011stage clinical uncertainty, regulatory decisions, and competitive dynamics in EGFR\u2011mutant NSCLC.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/688091_20260819_V2SL.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688091_20260819_V2SL.\"><\/object><a id=\"wp-block-file--media-0f565343-3e4d-4bf4-a5c2-c96078779abf\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/688091_20260819_V2SL.pdf\">688091_20260819_V2SL<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/688091_20260819_V2SL.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-0f565343-3e4d-4bf4-a5c2-c96078779abf\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Yizhong Pharmaceutical Co., Ltd (SHA: 688091) announced that the Investigational New Drug (IND) application&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[16,62,2783,2782],"class_list":["post-75325","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-sha-688091","tag-yizhong-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shanghai Yizhong Pharmaceutical&#039;s YXC\u2011002 Wins IND Approval \u2013 Fourth\u2011Generation Brain\u2011Penetrant EGFR\u2011TKI for Non\u2011Small Cell Lung Cancer Overcomes C797S Resistance - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Yizhong Pharmaceutical Co., Ltd (SHA: 688091) announced that the Investigational New Drug (IND) application for its self\u2011developed innovative drug YXC\u2011002, targeting non\u2011small cell lung cancer (NSCLC), has been officially approved, clearing the way for clinical trials of a next\u2011generation therapy designed to address key resistance and brain\u2011metastasis challenges in EGFR\u2011driven disease.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=75325\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shanghai Yizhong Pharmaceutical&#039;s YXC\u2011002 Wins IND Approval \u2013 Fourth\u2011Generation Brain\u2011Penetrant EGFR\u2011TKI for Non\u2011Small Cell Lung Cancer Overcomes C797S Resistance\" \/>\n<meta property=\"og:description\" content=\"Shanghai Yizhong Pharmaceutical Co., Ltd (SHA: 688091) announced that the Investigational New Drug (IND) application for its self\u2011developed innovative drug YXC\u2011002, targeting non\u2011small cell lung cancer (NSCLC), has been officially approved, clearing the way for clinical trials of a next\u2011generation therapy designed to address key resistance and brain\u2011metastasis challenges in EGFR\u2011driven disease.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=75325\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-19T04:38:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-19T04:38:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75325#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75325\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shanghai Yizhong Pharmaceutical&#8217;s YXC\u2011002 Wins IND Approval \u2013 Fourth\u2011Generation Brain\u2011Penetrant EGFR\u2011TKI for Non\u2011Small Cell Lung Cancer Overcomes C797S Resistance\",\"datePublished\":\"2026-08-19T04:38:40+00:00\",\"dateModified\":\"2026-08-19T04:38:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75325\"},\"wordCount\":468,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"SHA: 688091\",\"Yizhong Pharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75325#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75325\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=75325\",\"name\":\"Shanghai Yizhong Pharmaceutical's YXC\u2011002 Wins IND Approval \u2013 Fourth\u2011Generation Brain\u2011Penetrant EGFR\u2011TKI for Non\u2011Small Cell Lung Cancer Overcomes C797S Resistance - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-19T04:38:40+00:00\",\"dateModified\":\"2026-08-19T04:38:41+00:00\",\"description\":\"Shanghai Yizhong Pharmaceutical Co., Ltd (SHA: 688091) announced that the Investigational New Drug (IND) application for its self\u2011developed innovative drug YXC\u2011002, targeting non\u2011small cell lung cancer (NSCLC), has been officially approved, clearing the way for clinical trials of a next\u2011generation therapy designed to address key resistance and brain\u2011metastasis challenges in EGFR\u2011driven disease.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75325#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75325\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75325#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shanghai Yizhong Pharmaceutical&#8217;s YXC\u2011002 Wins IND Approval \u2013 Fourth\u2011Generation Brain\u2011Penetrant EGFR\u2011TKI for Non\u2011Small Cell Lung Cancer Overcomes C797S Resistance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shanghai Yizhong Pharmaceutical's YXC\u2011002 Wins IND Approval \u2013 Fourth\u2011Generation Brain\u2011Penetrant EGFR\u2011TKI for Non\u2011Small Cell Lung Cancer Overcomes C797S Resistance - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Yizhong Pharmaceutical Co., Ltd (SHA: 688091) announced that the Investigational New Drug (IND) application for its self\u2011developed innovative drug YXC\u2011002, targeting non\u2011small cell lung cancer (NSCLC), has been officially approved, clearing the way for clinical trials of a next\u2011generation therapy designed to address key resistance and brain\u2011metastasis challenges in EGFR\u2011driven disease.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=75325","og_locale":"en_US","og_type":"article","og_title":"Shanghai Yizhong Pharmaceutical's YXC\u2011002 Wins IND Approval \u2013 Fourth\u2011Generation Brain\u2011Penetrant EGFR\u2011TKI for Non\u2011Small Cell Lung Cancer Overcomes C797S Resistance","og_description":"Shanghai Yizhong Pharmaceutical Co., Ltd (SHA: 688091) announced that the Investigational New Drug (IND) application for its self\u2011developed innovative drug YXC\u2011002, targeting non\u2011small cell lung cancer (NSCLC), has been officially approved, clearing the way for clinical trials of a next\u2011generation therapy designed to address key resistance and brain\u2011metastasis challenges in EGFR\u2011driven disease.","og_url":"https:\/\/flcube.com\/?p=75325","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-19T04:38:40+00:00","article_modified_time":"2026-08-19T04:38:41+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=75325#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=75325"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shanghai Yizhong Pharmaceutical&#8217;s YXC\u2011002 Wins IND Approval \u2013 Fourth\u2011Generation Brain\u2011Penetrant EGFR\u2011TKI for Non\u2011Small Cell Lung Cancer Overcomes C797S Resistance","datePublished":"2026-08-19T04:38:40+00:00","dateModified":"2026-08-19T04:38:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=75325"},"wordCount":468,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Clinical trial approval \/ initiation","SHA: 688091","Yizhong Pharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=75325#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=75325","url":"https:\/\/flcube.com\/?p=75325","name":"Shanghai Yizhong Pharmaceutical's YXC\u2011002 Wins IND Approval \u2013 Fourth\u2011Generation Brain\u2011Penetrant EGFR\u2011TKI for Non\u2011Small Cell Lung Cancer Overcomes C797S Resistance - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-19T04:38:40+00:00","dateModified":"2026-08-19T04:38:41+00:00","description":"Shanghai Yizhong Pharmaceutical Co., Ltd (SHA: 688091) announced that the Investigational New Drug (IND) application for its self\u2011developed innovative drug YXC\u2011002, targeting non\u2011small cell lung cancer (NSCLC), has been officially approved, clearing the way for clinical trials of a next\u2011generation therapy designed to address key resistance and brain\u2011metastasis challenges in EGFR\u2011driven disease.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=75325#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=75325"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=75325#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shanghai Yizhong Pharmaceutical&#8217;s YXC\u2011002 Wins IND Approval \u2013 Fourth\u2011Generation Brain\u2011Penetrant EGFR\u2011TKI for Non\u2011Small Cell Lung Cancer Overcomes C797S Resistance"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75325","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=75325"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75325\/revisions"}],"predecessor-version":[{"id":75327,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75325\/revisions\/75327"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=75325"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=75325"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=75325"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}